Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit (Details Narrative)

Stockholders' Deficit (Details Narrative) - USD ($)					1 Months Ended		3 Months Ended				6 Months Ended		12 Months Ended
Stockholders' Deficit (Details Narrative) - USD ($)	May 12, 2019	Jul. 23, 2018	Jul. 20, 2018	Aug. 14, 2017	Mar. 27, 2019	Sep. 30, 2017	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Sep. 18, 2018
Common stock shares authorized							10,000,000,000				10,000,000,000		10,000,000,000	10,000,000,000
Common stock par value							$ 0.0001				$ 0.0001		$ 0.0001
Preferred stock shares authorized							5,000,000				5,000,000			5,000,000
Preferred stock par value							$ 0.01				$ 0.01			$ 0.01
Preferred stock, stated value							$ 1.00				$ 1.00
Number of common stock issued, value									$ 3,957,767
Common stock shares issued							6,008,936,775				6,008,936,775		128,567,273
Common stock shares outstanding							6,008,936,775				6,008,936,775		128,567,273
Recognized stock stock-based compensation											$ 17,300	$ 661,286
Remaining stock option expense											17,300
Interest expense							$ 5,400,000				9,500,000
Employees and Directors [Member] \| Restricted Stock [Member]
Number of restricted stock issued												142,667
Recognized stock stock-based compensation												$ 477,933
Stock issued price per share									$ 3.35			$ 3.35
2007 Equity Plan [Member]
Stock option expense											$ 17,300	$ 48,393
Weighted average period											6 years 9 months
Intrinsic value of options exercisable							$ 0				$ 0
2007 Equity Plan [Member] \| Restricted Stock [Member]
Number of restricted stock issued were forfeited											122
2007 Equity Plan [Member] \| Employees and Directors [Member] \| Restricted Stock [Member]
Number of restricted stock issued				364
Common Stock [Member]
Number of common stock issued								119,615,384	572,480	151,200	119,615,384
Number of common stock issued, value								$ 11,961	$ 57	$ 15
Cashless exercise warrants							755,000,000				755,000,000
Number of shares converted							2,505,054,118	3,255,700,000			5,760,754,118		106,335,991
Number of restricted stock issued										142,667
Warrants [Member]
Number of warrants issued as anti-dilution provision											582,000,000,000
Warrant expiration date	Mar. 31, 2022
Change in fair value of warrants	$ 5,400,000				$ 4,100,000
Series G Preferred Stock [Member]
Preferred stock shares authorized							14,000				14,000		14,000
Preferred stock par value							$ 0.01				$ 0.01		$ 0.01
Preferred stock shares outstanding							215				215		215
Preferred stock, stated value							$ 1,000				$ 1,000
Weighted average common stock price percentage											85.00%
Series H Preferred Stock [Member]
Preferred stock shares authorized							14,202				14,202		14,202
Preferred stock par value							$ 0.01				$ 0.01		$ 0.01
Preferred stock shares outstanding							10				10		60
Preferred stock, stated value							$ 1,000				$ 1,000
Weighted average common stock price percentage											85.00%
Series F Convertible Preferred Stock [Member]
Preferred stock shares outstanding							1,750,000				1,750,000
Series F Convertible Preferred Stock [Member] \| Genomas, Inc [Member]
Number of common stock issued						1,750,000
Number of common stock issued, value						$ 174,097
Stock conversion share price						$ 14,625
Conversion of stock into shares						120
Preferred stock price per share for unpaid dividend						$ 1.95
Series J Convertible Preferred Stock [Member]
Preferred stock shares outstanding							250,000				250,000
Number of common stock issued			250,000
Series J Convertible Preferred Stock [Member] \| Alcimede LLC [Member] \| Exchange Agreement [Member]
Preferred stock, stated value		$ 1.00
Number of common stock issued		250,000
Number of common stock issued, value		$ 250,000
Cumulative dividends percentage		8.00%
Series I-2 Preferred Stock [Member]
Number of shares converted											769.2276		1,286.141